RabAvert

BIOLOGICAL7 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), U.S. Army Medical Research and Development Command, Synermore Biologics Co., Ltd., Bio Products Laboratory, GlaxoSmithKline

Conditions

HealthyHealthy ParticipantsHealthy VolunteersHuman RabiesMalaria, FalciparumPrimary Immune DeficiencyVirus Diseases

Early Phase 1

Washington University WU 409: Immune Responses to Rabies Vaccine.

CompletedNCT07399951

Washington University School of MedicineHealthy Participants

Start: 2023-07-18End: 2025-10-01Updated: 2026-02-10

Phase 1

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

CompletedNCT02956746

Synermore Biologics Co., Ltd.Human Rabies

Start: 2016-08-31End: 2018-01-31Updated: 2019-02-27

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults

CompletedNCT04062669

GlaxoSmithKlineVirus Diseases

Start: 2019-08-13End: 2022-07-01Updated: 2024-03-01

A Study of RBI-4000 in Healthy Participants

TerminatedNCT06048770

Replicate BioscienceHealthy Volunteers

Start: 2023-09-01End: 2024-07-31Updated: 2024-08-06

Phase 2

Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine

CompletedNCT00223990

U.S. Army Medical Research and Development CommandMalaria, Falciparum

Start: 2005-04-08End: 2007-06-30Updated: 2021-02-12

Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects

CompletedNCT03264157

Bio Products LaboratoryHealthy

Start: 2017-12-08End: 2018-07-13Updated: 2020-02-25

Phase 4

Antibody Production in Immune Disorders

TerminatedNCT00023504

National Institute of Allergy and Infectious Diseases (NIAID)Primary Immune Deficiency

Start: 2002-06-13End: 2021-10-14Updated: 2021-10-15

Related Papers

Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial.

2025-09-24

Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers

Nature Communications2025-01-0724 citations

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

2022-01-14123 citations

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.

2021-09-0316 citations

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.

2009-03-05228 citations